Optimal Timing of Euploid Day 6 Blastocyst Transfer in Frozen HRT Cycles, Day 6 or Day 7 of Progesterone Administration.

• Status: Recruiting
• Trial end date: 2024-09-30
• Target enrollment: 0
• Participant gender: Female

Summary

The goal of this study is to compare the difference in clinical pregnancy, miscarriage and livebirth rate between day 6 euploid blastocyst transfer on the 6th and the 7th day of progesterone exposure in Hormonal Replacement Therapy (HRT) FET cycles. This prospective & randomized study will only include euploid day 6 blastocysts. This will be the first prospective study of euploid day 6 blastocysts thereby excluding aneuploidy as a cause of miscarriage and implantation failure. The point of randomization will occur on the day of progesterone commencement.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: ART Fertility Clinics LLC
• Treatments: Estradiol; Estradiol 17 beta-cypionate; Estradiol 3-benzoate; Polyestradiol phosphate; Progesterone

Criteria

Inclusion Criteria:

• Women aged 18 years to 43 years.

• Having at least 1 euploid cryopreserved day 6 blastocyst of at least Grade BB quality.

• Endometrial trilaminar appearance on the day of progesterone start

Exclusion Criteria:

• Uterine abnormality

• Hydrosalpinx

• Asherman syndrome

• Any known contraindications or allergy to oral estradiol or progesterone.

• Intention to treat : exclusion factors :

1. Spontaneous ovulation HRT cycle

2. Discontinuation of HRT medication